BLASUBCUTANEOUSSYRINGE
Approved
Mar 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
REBIF (interferon beta-1a) by Biogen is mechanism(s) by which rebif (interferon beta-1a) exerts its therapeutic effects in patients with multiple sclerosis is unknown. Approved for multiple sclerosis, relapsing-remitting. First approved in 2002.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REBIF (interferon beta-1a) is a subcutaneously administered interferon beta therapeutic approved in 2002 for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The exact mechanism by which REBIF exerts its therapeutic effects remains unknown, though it is classified as an interferon beta immunomodulator. As a first-generation disease-modifying therapy, REBIF represents an established treatment option in the MS market, though it now competes against a diverse pipeline of newer oral and infused agents with different mechanisms of action.
$0.1BPart D
Mechanism of Action
mechanism(s) by which REBIF (interferon beta-1a) exerts its therapeutic effects in patients with multiple sclerosis is unknown.
Pharmacologic Class:
Interferon beta
Indications (1)
Clinical Trials (20)
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
Started Apr 2021
470 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Started Oct 2019
152 enrolled
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
Started Mar 2019
11 enrolled
Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
Started Dec 2017
168 enrolled
Relapsing Remitting Multiple Sclerosis (RRMS)
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
Started Nov 2017
40 enrolled
BioequivalenceHealthy
Worked on REBIF at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.